Growth Investing
Pay up for companies expanding revenue and earnings faster than the market.
How it works
Growth investing buys companies whose sales and earnings are compounding rapidly, betting that future expansion justifies a high price today. Investors focus on total addressable market, revenue growth, competitive moats, and reinvestment, tolerating lofty valuation multiples and often zero dividends. The thesis is that a business doubling every few years will grow into and past its price. It favors innovative, disruptive firms, especially in technology and healthcare, and tends to overlap with price momentum because winners keep winning. The vulnerability is duration: much of the value sits in far-future cash flows, so rising rates or a growth stumble triggers sharp multiple compression.
The trade-offs
✅ Strengths
- Access to the biggest long-run compounders and innovators
- Can dramatically outperform in low-rate, risk-on regimes
- Winners can run far beyond conservative estimates
⚠️ Weaknesses
- Rich valuations mean brutal drawdowns when growth disappoints
- Highly sensitive to interest-rate increases
- Little margin of safety; priced for perfection
Publicly associated with
Naming a practitioner is historical, educational context — never an endorsement.
Legends who play this way
Play the Growth Investing style in Conviction League
Draft a critter that trades this way, train it on a simulated market, and backtest it on the leaderboard — free and fully simulated, so there's zero real-money risk.